Results from EVEREST II suggested percutaneous repair might lead to fewer adverse events than traditional valve surgery for mitral regurgitation. But many who saw the study presented had additional questions about the highly selected population, procedural failures, durability of the MR grade achieved, and how the results compared between the per-protocol analysis and the intention-to-treat analysis.